1
Discover top-quality products tailored for scientific and medical research. Request a personalized quote today
to enhance your projects.
| Product Code | Suit-2; SUIT 2; SUIT2; Suit2; SUIzo Tumor-2 |
| Species | Human |
| Cat.No | ABC-TC1175 |
| Product Category | Tumor Cell Lines |
| Size/Quantity | 1 vial |
| Cell Type | Epithelial-like |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 ℃, 5% CO2 |
| Biosafety Level | 1 |
| Storage | Liquid Nitrogen |
| Product Type | Human Pancreas Cancer Cell Lines |
SUIT-2 is a human pancreatic cancer cell line derived from a metastatic liver tumor. Under a phase-contrast microscope, two types of SUIT-2 can be seen in semiconfluent culture: a spindle-shaped and elongated form, and a polygonal and epithelium-like form. 
The population doubling time of SUIT-2 is about 31.1 hours when it grows in tissue culture, and it can be passaged in the serum-free medium using 0.05% trypsin solution in PBS(-). When SUIT-2 is transplanted in the nude mice, the metastasis to the regional lymph nodes is confirmed. Observed by electron microscope, SUIT-2 showed a characteristic of pancreatic ductal epithelium. SUIT-2 produces several tumor markers, such as carcinoembryonic antigen (CEA), carbohydrate antigen 19-9, CSPG2/versican, and Mac25/angiomodulin.
Why choose SUIT-2 from AcceGen?
AcceGen’s SUIT-2 is cultured with specific and standardized operating procedures. All cell lots show the maximum performance in terms of cell viability and cell morphology, as tested through rigorous and professional quality control.
When you publish your research, please cite our product as “AcceGen Biotech Cat.# XXX-0000”. In return, we’ll give you a $100 coupon. Simply click here and submit your paper’s PubMed ID (PMID).
Chen, W.C., To, M.D., Westcott, P.M., Delrosario, R., Kim, I.J., Philips, M., Tran, Q., Bollam, S.R., Goodarzi, H., Bayani, N. and Mirzoeva, O., 2021. Targeting KRAS4A splicing through the RBM39/DCAF15 pathway inhibits cancer stem cells. Nature communications, 12(1), pp.1-14.
FOR RESEARCH USE ONLY
Less than 5% of the patients diagnosed with pancreatic adenocarcinoma can survive beyond 24 months. SUIT-2 is a useful tool to investigate the biological activity of pancreatic ductal adenocarcinoma, identify novel targets or markers for diagnosis, prognosis, and therapy, and benefit to the understanding of the interactions between cancer and the host. For example, SUIT-2 can be used to illustrate the function of growth factor in cell proliferation of tumor cells and the effect of cell motility factor on migration and metastasis.
